| Distant metastasis-free survival | Overall survival | Disease-free survival | |||
---|---|---|---|---|---|---|
P | HR (95%CI) | P | HR (95%CI) | P | HR (95%CI) | |
Unadjusted cohort | ||||||
 Gender | 0.035* | 0.729 (0.543–0.978) | 0.348 | 0.859 (0.626–1.180) | 0.144 | 0.820 (0.628–1.070) |
 Age | 0.674 | 0.937 (0.693–1.267) | 0.165 | 1.247 (0.913–1.702) | 0.797 | 1.036 (0.792–1.355) |
 cT stage | 0.500 | 0.918 (0.715–1.178) | 0.757 | 0.959 (0.733–1.254) | 0.929 | 1.010 (0.806–1.266) |
 cN stage | 0.309 | 0.758 (0.445–1.292) | 0.821 | 1.074 (0.580–1.986) | 0.286 | 0.772 (0.480–1.242) |
 Pretreatment CEA | 0.072 | 1.265 (0.979–1.634) | 0.076 | 1.284 (0.975–1.691) | 0.110 | 1.208 (0.958–1.523) |
 Type of radiation | 0.673 | 1.073 (0.772–1.492) | 0.836 | 0.962 (0.668–1.386) | 0.849 | 0.970 (0.707–1.330) |
 Concurrent chemotherapy | 0.871 | 0.973 (0.695–1.361) | 0.682 | 1.073 (0.765–1.506) | 0.820 | 0.967 (0.724–1.291) |
 Adjuvant chemotherapy | 0.112 | 1.379 (0.927–2.052) | 0.814 | 0.954 (0.641–1.418) | 0.182 | 1.265 (0.896–1.786) |
 pCR | 0.796 | 1.119 (0.477–2.626) | 0.003* | 3.634 (1.532–8.623) | 0.160 | 1.648 (0.820–3.312) |
 ypT stage | < 0.001* | 2.066 (1.598–2.670) | < 0.001* | 1.902 (1.497–2.417) | < 0.001* | 1.770 (1.431–2.188) |
 ypN stage | < 0.001* | 1.768 (1.439–2.172) | < 0.001* | 2.048 (1.639–2.558) | < 0.001* | 1.941 (1.615–2.331) |
 RCRG | 0.817 | 0.992 (0.923–1.066) | 0.133 | 1.050 (0.985–1.120) | 0.287 | 1.031 (0.975–1.091) |
PS-adjusted cohort | ||||||
 Gender | 0.414 | 0.854 (0.584–1.248) | 0.923 | 1.021 (0.666–1.565) | 0.510 | 0.893 (0.636–1.252) |
 Age | 0.856 | 1.036 (0.707–1.519) | 0.029* | 1.562 (1.047–2.330) | 0.291 | 1.196 (0.858–1.668) |
 cT stage | 0.629 | 0.921 (0.660–1.285) | 0.492 | 1.138 (0.787–1.643) | 0.591 | 1.086 (0.804–1.466) |
 cN stage | 0.469 | 0.773 (0.385–1.551) | 0.768 | 1.127 (0.508–2.500) | 0.828 | 0.932 (0.494–1.758) |
 Pretreatment CEA | 0.011* | 1.526 (1.101–2.116) | 0.013* | 1.578 (1.100–2.263) | 0.013* | 1.447 (1.081–1.937) |
 Type of radiation | 0.438 | 1.182 (0.775–1.802) | 0.492 | 1.169 (0.749–1.825) | 0.712 | 1.072 (0.743–1.546) |
 Concurrent chemotherapy | 0.855 | 0.964–0.651-1.429) | 0.482 | 1.163 (0.764–1.769) | 0.775 | 0.950 (0.670–1.348) |
 Adjuvant chemotherapy | 0.040* | 1.771 (1.027–3.053) | 0.919 | 1.027 (0.612–1.724) | 0.194 | 1.338 (0.862–2.077) |
 pCR | 0.383 | 0.623 (0.215–1.804) | 0.256 | 1.864 (0.636–5.466) | 0.960 | 1.022 (0.443–2.359) |
 ypT stage | 0.001* | 1.701 (1.240–2.334) | 0.037* | 1.430 (1.023–2.000) | 0.005* | 1.459 (1.121–1.899) |
 ypN stage | < 0.001* | 1.903 (1.457–2.487) | < 0.001* | 2.253 (1.680–3.022) | < 0.001* | 2.023 (1.594–2.566) |
 RCRG | 0.577 | 1.027 (0.935–1.129) | 0.243 | 1.056 (0.964–1.157) | 0.365 | 1.037 (0.959–1.122) |